369 related articles for article (PubMed ID: 30361677)
41. Using pharmacists to improve risk stratification and management of stage 3A chronic kidney disease: a feasibility study.
Chang AR; Evans M; Yule C; Bohn L; Young A; Lewis M; Graboski E; Gerdy B; Ehmann W; Brady J; Lawrence L; Antunes N; Green J; Snyder S; Kirchner HL; Grams M; Perkins R
BMC Nephrol; 2016 Nov; 17(1):168. PubMed ID: 27825313
[TBL] [Abstract][Full Text] [Related]
42. Is lipid management effective for all stages of CKD?
Ku E; Campese V
Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543
[TBL] [Abstract][Full Text] [Related]
43. Treatment of Hyperlipidemia Changes With Level of Kidney Function-Rationale.
Ananthakrishnan S; Kaysen GA
Adv Chronic Kidney Dis; 2016 Jul; 23(4):247-54. PubMed ID: 27324678
[TBL] [Abstract][Full Text] [Related]
44. [Not Available].
Riesen WF
Praxis (Bern 1994); 2017 Aug; 106(17):921-926. PubMed ID: 28830328
[No Abstract] [Full Text] [Related]
45. Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias.
Packard CJ
Curr Cardiol Rep; 2018 Jun; 20(8):60. PubMed ID: 29904807
[TBL] [Abstract][Full Text] [Related]
46. Serum lipids and prevention of atherosclerotic cardiovascular events in hemodialysis patients.
Shoji T
Clin Exp Nephrol; 2014 Apr; 18(2):257-60. PubMed ID: 24072417
[TBL] [Abstract][Full Text] [Related]
47. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
48. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
Ballantyne CM; Shah S; Kher U; Hunter JA; Gill GG; Cressman MD; Ashraf TB; Johnson-Levonas AO; Mitchel YB
Am J Cardiol; 2017 Feb; 119(3):388-396. PubMed ID: 27956003
[TBL] [Abstract][Full Text] [Related]
49. Type of dyslipidemia and achievement of the LDL-cholesterol goal in chronic kidney disease patients at the University Hospital.
Sangsawang T; Sriwijitkamol A
Vasc Health Risk Manag; 2015; 11():563-7. PubMed ID: 26604773
[TBL] [Abstract][Full Text] [Related]
50. The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future.
Hajhosseiny R; Sabir I; Khavandi K; Wierzbicki AS
Clin Pharmacol Ther; 2014 Jul; 96(1):64-73. PubMed ID: 24699033
[TBL] [Abstract][Full Text] [Related]
51. Management of dyslipidemias in patients with diabetes and chronic kidney disease.
Molitch ME
Clin J Am Soc Nephrol; 2006 Sep; 1(5):1090-9. PubMed ID: 17699330
[TBL] [Abstract][Full Text] [Related]
52. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
Auer J; Berent R
Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
[TBL] [Abstract][Full Text] [Related]
53. The lipid story in chronic kidney disease: a long story with a happy end?
Kujawa-Szewieczek A; Więcek A; Piecha G
Int Urol Nephrol; 2013 Oct; 45(5):1273-87. PubMed ID: 23054316
[TBL] [Abstract][Full Text] [Related]
54. Still a reasonable goal: Targeting cholesterol in dialysis and advanced chronic kidney disease patients.
Heine GH; Rogacev KS; Weingärtner O; Marsche G
Semin Dial; 2017 Sep; 30(5):390-394. PubMed ID: 28628255
[TBL] [Abstract][Full Text] [Related]
55. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
56. Lipid-modifying therapy in chronic kidney disease: Pathophysiological and clinical considerations.
Heine GH; Eller K; Stadler JT; Rogacev KS; Marsche G
Pharmacol Ther; 2020 Mar; 207():107459. PubMed ID: 31863818
[TBL] [Abstract][Full Text] [Related]
57. Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.
Kon V; Yang H; Fazio S
Arch Med Res; 2015 Jul; 46(5):379-91. PubMed ID: 26009251
[TBL] [Abstract][Full Text] [Related]
58. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
Brea Hernando ÁJ
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
[TBL] [Abstract][Full Text] [Related]
59. Dyslipidemia in Patients with Kidney Disease.
Thobani A; Jacobson TA
Cardiol Clin; 2021 Aug; 39(3):353-363. PubMed ID: 34247749
[TBL] [Abstract][Full Text] [Related]
60. Managing dyslipidaemia in type 2 diabetes mellitus.
Szalat A; Durst R; Leitersdorf E
Best Pract Res Clin Endocrinol Metab; 2016 Jun; 30(3):431-44. PubMed ID: 27432076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
